D. A. Parks, H. C. Jennings, C. Taylor, G. E. Pakes and E. P. Acosta, “Steady-State Amprenavir, Tenofovir, and Emtricitabine Pharmacokinetics before and after Reducing Ritonavir Boosting of a Fosamprenavir/Tenofovir/Emtricitabine Regimen from 200 mg to 100 mg Once Daily (TELEX II),” HIV Clinical Trials, Vol. 10, No. 3, 2009, pp. 160-167. doi:10.1310/hct1003-160

has been cited by the following article:

• TITLE: Impact of Switch to Fosamprenavir and Addition of Lovaza® for Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy

  AUTHORS: Franco Felizarta, Anthony Scarsella, Homayoon Khanlou, Winston Young, Lisa Ross, Henry Zhao, Keith Pappa, Belinda Ha

  KEYWORDS: Fish Oil; Fosamprenavir; HIV; Hypertriglyceridemia; Lovaza; Switch; Triglycerides

  JOURNAL NAME: World Journal of AIDS, Vol.2 No.1, March 22, 2012

  ABSTRACT: Background: Managing hypertriglyceridemia in HIV-infected patients often requires multiple pharmacologic strategies. Many protease inhibitors (PIs), one of 6 classes of drugs used to treat HIV, have been associated with hypercholesterolemia and drug interactions. For this study, we examined a dual strategy to manage hypertriglyceridemia in HIV-infected patient taking PIs: 1) switching patients to fosamprenavir (FPV), a PI with fewer drug interactions, and 2) adding prescription fish oil (LOVAZA?), which has been shown to reduce triglycerides. Methods: This multicenter, 24-week study enrolled 36 patients virologically suppressed (HIV-1 RNA